Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

The Multi-center Validation Study of Internal Mammary Lymph Biopsy With Modified Injection Technique in Breast Cancer Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03024463
Recruitment Status : Unknown
Verified May 2018 by Yongsheng Wang, Shandong Cancer Hospital and Institute.
Recruitment status was:  Recruiting
First Posted : January 18, 2017
Last Update Posted : May 21, 2018
Sponsor:
Information provided by (Responsible Party):
Yongsheng Wang, Shandong Cancer Hospital and Institute

Brief Summary:

In addition to axillary lymph node (ALN), internal mammary lymph node (IMLN) chain is also the first-echelon nodal drainage site for metastasis and it provides important prognostic information in breast cancer patients. However, decision about local treatment of IMLN is still being made based on ALN status. The 2016 National Comprehensive Cancer Network Guidelines recommend internal mammary lymph node irradiation for patients with more than 4 positive ALNs (category 1), and strongly consider irradiation for patients with 1 to 3 positive ALNs (category 2A). Therefore, there will be patients in positive ALN subgroup who just face complications of an unnecessary radiation to IMLN and there will be patients in negative ALN subgroup who do not receive adjuvant radiation therapy they really need. Thus, these inclusion criteria of National Comprehensive Cancer Network might lead to over-treatment and under-treatment. Internal mammary sentinel lymph node biopsy (IM-SLNB) provides a less invasive method of assessing the IMLN than surgical dissection. However, low visualization rate of IM-SLN has been a restriction of IM-SLNB. A modified radiotracer injection technique was established in our previous study. This technique could significantly improve the IM-SLN detection rate. The investigators have validated the accurate of the hypothesis and the modified radiotracer injection technique in the previous study.

For axillary sentinel lymph node biopsy, the success rate and the accuracy are the most important technical indicators. The relatively lower false-negative rate is a precondition for the widely application of SLNB. Axillary SLNB needs to be accomplished with the cooperation of multi-disciplinary teamwork, including the breast surgery, the radiologist, the nuclear medicine doctor and the pathologist, in order to obtain a better success rate and a lower false-negative rate. Our previous studies confirmed that the modified radiotracer injection technique can greatly improve the IM-SLN detection rate. However, whether the IM-SLNB based on the modified radiotracer injection technique has a low false negative rate or not still need to be confirmed by a further validation research.

Furthermore,recently, the investigators propose that if IM-SLN is the only metastatic lymph node and there would be no positive node else in IMLN chain, the radiotherapy and its associated complications could be avoided in these patients. On the other hand, if there is the presence of metastatic non-sentinel lymph node (NSLN) in IMLN chain after IM-SLNB, it is important to predict the risk of IM-NSLN metastasis in IM-SLN positive patients. As there is currently no such model, a predictive model for IM-SLN positive patients to avoid radiotherapy is needed in this situation. Therefore, a new study will be conducted to verify the issues above.

In the current study, all the participants (18~70 years of age) would have the preoperative pathology of invasive breast cancer and positive fine-needle aspiration result in their clinical or ultrasonic suspicious axillary lymph node. 99mTc-labeled sulfur colloid was injected into the parenchyma under the ultrasound guidance 3 to 18 hours before surgery. Two syringes of 9.25 to 18.5MBq 99mTc-labeled sulfur colloid in 0.5 to 0.7mL volume were injected at the 6 and 12 o'clock positions 0.5 to 1.0 cm from areola (about 2.0~4.0 cm from the nipple). IM-SLNB was performed in all participants with IMSLN visualized on preoperative lymphoscintigraphy and/or detected by the intra-operative gamma probe. All hotspots in the internal mammary basin were harvested and intra-operative identification of the IM-SLN was based on gamma probe detection. The IM-SLN was sectioned along the long axis into two blocks and all blocks were tested by the frozen section and the touch imprint cytology intra-operatively. Those participants with positive intra-operative results received IMLN dissection. Finally, all the IM-SLN blocks and IM-NSLN dissected were assessed post-operatively by H&E and Cytokeratin 19 stained immunohistochemistry. The conclusion would be drawn through the results mentioned above.


Condition or disease Intervention/treatment
Breast Neoplasm Procedure: IM-SLNB and IMLN dissection

Layout table for study information
Study Type : Observational
Estimated Enrollment : 200 participants
Observational Model: Case-Only
Time Perspective: Prospective
Official Title: The Multi-center Validation Study of Breast Cancer Internal Mammary Lymph Biopsy
Actual Study Start Date : August 1, 2017
Estimated Primary Completion Date : March 1, 2019
Estimated Study Completion Date : August 1, 2019

Resource links provided by the National Library of Medicine



Intervention Details:
  • Procedure: IM-SLNB and IMLN dissection
    Internal mammary sentinel lymph node biopsy followed by internal mammary lymph node dissection


Primary Outcome Measures :
  1. The accuracy (false negative rate) of internal mammary sentinel lymph node biopsy [ Time Frame: Two years ]

Secondary Outcome Measures :
  1. The number of internal mammary non-sentinel lymph node metastases in patients with positive axillary node and internal mammary sentinel lymph node [ Time Frame: Two years ]
  2. Factors influencing the number of internal mammary non-sentinel lymph node metastases in patients with positive axillary node and internal mammary sentinel lymph node [ Time Frame: Two years ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population
200 patients with positive axillary node
Criteria

Inclusion Criteria:

  • Patients with preoperative pathology confirmed invasive breast cancer;
  • Clinical N1-3 M0 (with positive fine-needle aspiration result in their clinical or ultrasonic suspicious axillary lymph node ; no clinical or radiologic evidence of distant metastases);
  • Be able and willing to sign informed consent forms.

Exclusion Criteria:

  • Patients who have received neoadjuvant therapy (including neoadjuvant chemotherapy and / or endocrine therapy);
  • Patients with a previous history of breast cancer (recurrence of breast cancer and contralateral breast cancer);
  • Patients with a history of other malignancies;
  • Patients who have had previous surgery in axillary or internal mammary;
  • Patients in pregnancy and lactation;
  • Patients participant in other clinical trials that will have an impact on the results of this study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03024463


Locations
Layout table for location information
China, Shandong
Shandong Cancer Hospital and Institute Recruiting
Jinan, Shandong, China, 250117
Contact: Yong-sheng Wang, MD    +8613505409989    wangysh2008@aliyun.com   
Principal Investigator: Yong-sheng Wang, MD         
Sponsors and Collaborators
Shandong Cancer Hospital and Institute

Layout table for additonal information
Responsible Party: Yongsheng Wang, Director of Breast Cancer Center, Shandong Cancer Hospital and Institute
ClinicalTrials.gov Identifier: NCT03024463    
Other Study ID Numbers: IMLN-VS
First Posted: January 18, 2017    Key Record Dates
Last Update Posted: May 21, 2018
Last Verified: May 2018

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Yongsheng Wang, Shandong Cancer Hospital and Institute:
Breast Neoplasm; Internal Lymph Node; Sentinel Lymph Node Biospy
Additional relevant MeSH terms:
Layout table for MeSH terms
Breast Neoplasms
Neoplasms
Neoplasms by Site
Breast Diseases
Skin Diseases